Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...

Leerink notes Eli Lilly (LLY) terminated its volenrelaxin CKD due to failure of a “related heart failure study,” which has caused significant ...

Tectonic Therapeutic (TECX) plunges as Eli Lilly (LLY) ends a mid-stage trial for its kidney drug volenrelaxin which is similar to TECX's lead drug TX45. Read more here.

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $808.17 which represents a slight increase of $22.76 or 2.90% from the prior close of $785.41. The stock opened at $780.91 and ...

Shares of Tectonic plummeted 41% Tuesday following news that a similar drug developed by Eli Lilly (NYSE: LLY) for chronic ...

For Hoosiers seeking a fresh start or a pathway to a fulfilling career, the Lilly Scholars at Ivy Tech scholarships offer a ...